News
AEZS
2.190
+5.29%
0.110
Aeterna Zentaris Announces Merger Approval
TipRanks · 8h ago
Aeterna Zentaris Announces Merger with Ceapro Inc.
Aeterna Zentaris Inc. Is set to merge with Ceapro Inc. The all-stock merger is expected to be completed in the second quarter of 2024. The move is anticipated to enhance their offerings in pharmaceutical and diagnostic products. TSE:AEZS has received final court approval for the merger.
TipRanks · 12h ago
*AEterna Zentaris and Ceapro Anticipate Completing the Transaction in the 2Q of 2024 >AEZS
Dow Jones · 12h ago
*Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris AEZS
Dow Jones · 12h ago
AEZS Stock Earnings: AEterna Zentaris Misses EPS for Q4 2023
AEterna Zentaris reported earnings per share of -$1.16. This was below the analyst estimate for EPS of -97 cents. The company reported revenue of $121,000. The stock was down 2.7% after the market closed on Wednesday.
Investorplace · 1d ago
Aeterna Zentaris Financials Affirm Compliance
TipRanks · 1d ago
Aeterna Zentaris Completes Key Trial Enrollment
TipRanks · 1d ago
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 1d ago
AEterna Zentaris: Q4 Earnings Insights
AEterna Zentaris reported its Q4 earnings on March 27. The company missed estimates by $0.16. AEterna zentaris is expected to report earnings of $-1.16 per share. Last quarter the company missed by $1.24 and the share price dropped 6.0%.
Benzinga · 1d ago
Aeterna Zentaris Completes Trial Enrollment, Plans Merger
TipRanks · 1d ago
Aeterna Zentaris Inc: Report of foreign issuer
Press release · 1d ago
Aeterna Zentaris reports Q4 results
Aeterna Zentaris reports Q4 results. Q4 total revenue for was $0.1 million. The company reported an EPS loss of $1.16 in the fourth quarter. The Company's agreement with Novo Nordisk Healthcare was terminated in May 2023.
Seeking Alpha · 1d ago
Aeterna Zentaris: Q4 Earnings Snapshot
Aeterna Zentaris Inc. Reports loss of $5.6 million in its fourth quarter. Drug developer posted revenue of $121,000 in the period. For the year, company's loss narrowed to $16.5 million. The company's shares closed at $2.63 on Wednesday.
Barchart · 1d ago
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Barchart · 1d ago
Weekly Report: what happened at AEZS last week (0318-0322)?
Weekly Report · 3d ago
Shortened Week Due to Easter Holiday
U.S. Featured Earnings include PVH Corp. And GameStop Corp. On Monday and Tuesday. Canada's economic lookahead includes new home sales and employment growth. The S&P Case-Shiller home price index and pending home sales will be released on Tuesday.
Barchart · 6d ago
Weekly Report: what happened at AEZS last week (0311-0315)?
Weekly Report · 03/18 10:58
Aeterna Zentaris, Ceapro Merger Wins Approval
TipRanks · 03/12 18:37
*Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Dow Jones · 03/12 18:10
Weekly Report: what happened at AEZS last week (0304-0308)?
Weekly Report · 03/11 10:56
More
Webull provides a variety of real-time AEZS stock news. You can receive the latest news about Aeterna Zentaris Inc through multiple platforms. This information may help you make smarter investment decisions.
About AEZS
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.